Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses.
Authors: Hainisch E K, Brandt S, Shafti-Keramat S, Van den Hoven R, Kirnbauer R
Journal: Equine veterinary journal
Summary
# Editorial Summary: BPV-1 Vaccination Trial in Horses Equine sarcoids represent a significant welfare and economic problem with limited treatment options, driven by persistent bovine papillomavirus (BPV) infection that current therapies struggle to resolve. Researchers evaluated the safety and immune response to an experimental BPV-1 L1 virus-like particle (VLP) vaccine administered at escalating doses to horses, drawing on the established efficacy of VLP-based immunisation against papillomaviruses in other species. The dose-escalation design allowed investigators to identify optimal vaccination schedules whilst monitoring for adverse reactions and measuring antibody responses to determine whether horses could mount protective immunity. Key findings regarding immunogenicity levels and safety thresholds should inform whether this vaccine candidate warrants progression to efficacy trials, potentially offering the first prophylactic option against sarcoid development. If successful in preventing BPV-1 infection, such a vaccine could substantially reduce the prevalence of therapy-resistant sarcoids and the associated economic burden on equine practice, particularly for horses at high risk or in endemic populations.
Read the full abstract on PubMed
Practical Takeaways
- •A potential prophylactic vaccine for equine sarcoids may be available in future, offering prevention of this common and difficult-to-treat condition
- •Veterinarians should monitor vaccine development for BPV-related disease as this represents a major gap in current equine preventive medicine
- •Early vaccination could reduce the economic burden and welfare impact of sarcoid disease in affected horses and herds
Key Findings
- •BPV-1 L1 virus-like particles were evaluated in a dose-escalation vaccination trial in horses
- •Immunisation with papillomavirus-like particles (VLP) has demonstrated protective efficacy against papillomaviral infection in multiple animal species
- •Sarcoids are therapy-resistant skin tumours caused by BPV-1 and BPV-2 infection in equids with significant animal welfare and economic implications